Clinical trials
Bone Metastases in Subjects With Advanced Cancer clinical trials
Below are recruiting bone metastases in subjects with advanced cancer clinical trials, each written for real people, not researchers. We’re tracking 271 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07113925RecruitingPhase 1
Testing TQB2101 for advanced blood cancers
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
Zhengzhou, HenanAges 18–75 - NCT07718490RecruitingPhase 2
Immunotherapy with simvastatin and chemo for advanced colorectal cancer
This trial tests a new combination of immunotherapy, simvastatin (a cholesterol drug), and standard chemotherapy for advanced colorectal cancer that has not been treated before. The goal is to see if adding simvastatin can help the immune system fight the cancer better.
Nanjing, JiangsuAges 18–75 - NCT06555068RecruitingPhase 1/Phase 2
Study of HRS-6209 combinations for advanced breast cancer
This trial tests a new drug, HRS-6209, combined with different hormone treatments (fulvestrant, letrozole, HRS-8080, or HRS-1358) for people with advanced breast cancer that has spread or cannot be surgically removed and has worsened after previous treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06679036RecruitingPhase 1/Phase 2
Combination therapy for advanced breast cancer
This trial tests new drug combinations for advanced or metastatic breast cancer. It aims to see if adding HRS-2189, HRS-6209, or HRS-1358 to standard treatments works better. Participants must have tried certain hormone therapies or chemotherapies before.
Harbin, HeilongjiangAges 18–75 - NCT07414316RecruitingEarly Phase 1
GK01 cell therapy for advanced lung or esophageal cancer
This trial tests a new cell treatment called GK01 for people with advanced lung cancer or esophageal cancer that has not responded to standard treatments. The study aims to see if this therapy can help shrink tumors or slow the cancer's growth.
NanchangAges 18–75 - NCT04495296RecruitingPhase 1/Phase 2
TST001 for advanced or metastatic solid tumors
This Phase 1/2 study tests TST001, and sometimes a combination with other cancer medicines, to see how safe it is and how well it may work in advanced or metastatic solid tumors. You might be eligible if you have certain tumor types and lab/health requirements, and if your tumor tissue shows specific marker results (depending on the study part).
Bengbu, AnhuiAges 18 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Birmingham, AlabamaAges 18 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT07608848RecruitingEarly Phase 1
Imaging study of new cancer-targeting radioactive drugs
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
Perth, Western AustraliaAges 18 years+ - NCT06868732RecruitingPhase 1
A new drug combination for advanced non-small cell lung cancer
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06917092RecruitingPhase 2
New treatment for advanced endometrial cancer after prior therapy
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
TianjinAges 18–70 - NCT07459751RecruitingPhase 2/Phase 3
A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Duarte, CaliforniaAges 18 years+ - NCT06006013RecruitingPhase 2
Cabozantinib and pembrolizumab for adrenal cancer
This trial tests a combination of two drugs (cabozantinib and pembrolizumab) for adrenal cancer that has spread or cannot be removed by surgery. It may be an option if you have not had treatment before or have already tried other therapies.
Atlanta, GeorgiaAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Duarte, CaliforniaAges 18 years+ - NCT06970795RecruitingPhase 1
Study of SYS6040 for advanced solid tumors
This trial tests a new drug called SYS6040 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Changchuan, JilinAges 18 years+ - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT06873555RecruitingPhase 1/Phase 2
Study of a new drug for ovarian cancer and other advanced solid tumors
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
Bengbu, AnhuiAges 18 years+ - NCT06227156RecruitingPhase 2
Targeted drug for HER2-positive castration-resistant prostate cancer
This trial tests a new drug called Disitamab Vedotin for men with advanced prostate cancer that is no longer responding to hormone therapy. The drug targets a protein called HER2 on cancer cells to try to shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05398861RecruitingPhase 2
Testing utidelone plus bevacizumab for HER2-negative advanced breast cancer
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
Zhengzhou, HenanAges 18–70 - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75 - NCT07044908RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new drug called TQB2922 combined with TAS-102, with or without bevacizumab, for people whose advanced colorectal cancer has a normal RAS and BRAF gene and has not responded to standard chemotherapy. The goal is to see if this combination can slow or stop cancer growth.
Hefei, AnhuiAges 18–75 - NCT05332002RecruitingPhase 2
Study chemotherapy plus immunotherapy for HER2-negative esophageal cancer
This Phase 2 trial tests a combination treatment called sFOLFOXIRI for advanced esophageal or stomach-area cancer that is HER2-negative. It aims to see how well the treatment works and whether it is safe for people who have not had standard chemotherapy for this metastatic cancer yet.
Hamilton, New JerseyAges 18 years+ - NCT07139067RecruitingPhase 1
YK1101 for advanced solid tumors
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
BeijingAges 18–75
Hear when a new Bone Metastases in Subjects With Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bone metastases in subjects with advanced cancer?
- Yes. Clin2 currently lists 271 recruiting bone metastases in subjects with advanced cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bone metastases in subjects with advanced cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bone metastases in subjects with advanced cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.